Parkinson’s disease is a disorder of the central nervous system that affects movement, often including tremors. This causes a gradual loss of muscle control. While treatment can help, there is no known cure. Those with Parkinson’s disease have nerve cell damage in their brains which causes dopamine levels to drop. Dopamine is an essential neurotransmitter in the human brain, responsible for transmitting information among neurons and helping with the regulation of various functions, such as movement and emotional responses.
Early signs of Parkinson’s disease
- Difficulty getting out of a chair
- Trouble sleeping
- Trouble walking
- Impaired Balance
- Hunching over or stooping
- Voice becomes soft or low
- Fainting or dizziness
- Facial Masking (frozen in a serious expression)
How does CBD help Parkinson’s Disease?Studies have shown that patients with Parkinson’s disease show improvements in sleep, pain, bradykinesia, tremors, rigidity, motor impairments, and disability after being treated with CBD. CBD was also found to have neuroprotective effects on dopamine-producing cells. These effects may be due to the antioxidant or anti-inflammatory properties of CBD. Additionally, CBD helps in the reduction of pain and motor symptoms within 30 minutes of administration. The fact that CBD is anxiolytic enables it to improve mood and sleep patterns while decreasing psychosis among Parkinson’s disease sufferers. A 2017 study concluded that CBD might help the movement impairments in Parkinson’s and Alzheimer’s disease by interacting with a receptor known as GPR6. These studies suggest that CBD could potentially slow the progression of Parkinson’s by providing neuroprotective effects. CBD is shown to suppress the excitotoxicity, glial activation and oxidative injury that cause the degeneration of the dopamine-releasing neurons.
- Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.
- GPR3 and GPR6, novel molecular targets for cannabidiol
- Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures
- Self-Reported Efficacy of Cannabis and Other Complementary Medicine Modalities by Parkinson’s Disease Patients in Colorado
- Survey on Cannabis Use in Parkinson’s Disease: Subjective Improvement of Motor Symptoms
- The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1-2 phosphorylation in 6-OHDA-lesioned rats
- The influence of cannabinoids on generic traits of neurodegeneration